Life Sciences Tools and Services

WUXI XDC

WuXi XDC to Use Up to $100 Million for Share Buyback

Eastern Securities Maintains Buy Rating on WuXi XDC Cayman Inc.

CLSA Raises Target Price for Wuxi Holon to HKD80.9

Goldman Sachs Publishes Report on WuXi BodyCall's Earnings

Morgan Stanley Publishes Report on Wuxi Biologics

WuXi BodyLink Announces 69.9% Increase in Net Profit to 1.559 Billion RMB in 2024

WUXI XDC released FY2025 9 Months Earnings on March 23, 2026 (BJT), actual revenue HKD 4.697 B, actual EPS HKD 0.9179

WUXI XDC released FY2025 Q3 earnings on March 23, 2026 (BJT), with actual revenue of HKD 1.773 B and actual EPS of HKD 0.3007

WuXi Holistic 2025 Financial Year Gross Profit and Revenue Soar

WUXI XDC released FY2025 Annual Earnings on March 23 During-Market BJT, actual revenue HKD 0 (forecast HKD 6.608 B), actual EPS HKD 0 (forecast HKD 1.3797)

WUXI XDC released FY2025 Q4 earnings on March 23 During-Market (BJT), actual revenue HKD 1.803 B, actual EPS HKD 0.3059

WuXi Advanced Therapies Extends Tender Offer Deadline for Dongyao Pharmaceuticals

WUXI XDC to release FY2025 earnings on March 23 During-Market BJT, forecast revenue HKD 6.736 B, EPS HKD 1.4063

CMBI cuts Wuxi Biologics' revenue forecast for next three years but maintains 'buy' rating

Morgan Stanley Downgrades Wyeth Alliance's Profit Forecast and Target Price

Macquarie Recommends Buying Shares of Wuxi Biologics and Wuxi Apptec

Nomura Downgrades WuXi Henlius 2025 Revenue and Profit Forecast and Upgrades 2026 Target Price

WuXi Advanced Therapies Cayman to Hold Board Meeting to Approve 2025 Annual Report

WuXi Xullink Acquires East 曜 Pharmaceutical at a High Premium

WuXi BODYLOGIC Expects Significant Growth in Revenue and Net Profit in 2025 and Announces Acquisition of Tonex Pharmaceuticals

I.CENTURY HLDG

RIVERINE CHINA

AEC GROUP

KOS TALENT GP

TOP EDUCATION

C&N HOLDINGS

RICI HEALTH

ZXZN QI-HOUSE

HUISHENG INTL

XL2CSOPHYNIX

02268

WUXI XDCopened 2.15% higher at HKD54.55, with 19,600 shares traded. The company announced a plan to buy back up to USD100 million in shares, believing the current trading price does not reflect its intrinsic value or business prospects.

AASTOCKS News

WUXI XDC Opens 2.15% Higher w/ Plan of Share Buyback of Up to USD100M

WXXWY

02269

588130

513120

159992

510660

520690

513060

512290

Earendil Labs has announced the successful dosing of the first cohort in a Phase I clinical trial for HXN-1011, a novel biparatopic antibody targeting Thymic Stromal Lymphopoietin (TSLP). This antibody shows high affinity and blocks TSLP receptor interactions, demonstrating potent activity in preclinical studies. The company aims to develop innovative treatments for various immunological disorders, emphasizing their commitment to advancing next-generation biologics therapies.

prnewswire

WuXi Biologics

WUXI BIO

Sanofi

iShares US Pharma

China Southern Hang Seng Biotech ETF(QDII)

Ark Genomic Revolution ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Health Care Select Sector SPDR

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

First Trust NYSE Arca Biotech Index Fd

E Fund CSI 300 Health Care ETF

Huaan Hang Seng Biotech ETF

VG Health

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

Penghua SSE STAR Biology and Medicine ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

SPDR S&P Biotech

Minsheng Royal CSI Biotechnology Theme ETF

Penghua CSI HK Connect Health Care Composite ETF

Tianhong CNI BIOMEDICINE ETF

Yinhua CSI Innovative Drugs Industry ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Merchants CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

iShares Biotechnology ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Bosera Hang Seng Health Care ETF(QDII)

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

Guotai CSI Bio-medicine ETF

07:00 ETEarendil Labs Announces First Cohort Dosed in Phase I Study of Novel Biparatopic Antibody Targeting Thymic Stromal Lymphopoietin (TSLP)

02509

603259

588860

JPMorgan's report highlights the National Healthcare Security Administration's new plan for the 2026 National Reimbursement Drug List, which allows drugs to apply for NRDL inclusion before formal approval. This change is expected to enhance the commercialization prospects for innovative drug developers in China. The report identifies INNOVENT BIO, WUXI APPTEC, WUXI XDC, and SKB BIO as top picks, benefiting from clearer pricing rules and faster market access for high-priced drugs.

QYUNS-B

WuXi AppTec

WUXI APPTEC

SKB BIO

TEDA BIOMEDICAL

INNOVENT BIO

ICBCCS SSE STAR Biology and Medicine ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Guotai SSE STAR Brand Name Drug ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

JPMorgan Chase

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

JPM: NRDL Adjustment to Accelerate Commercialization of Innovative Drugs; Top Picks INNOVENT BIO , WUXI APPTEC , WUXI XDC , SKB BIO

WuXi XDC Cayman, Inc. has completed voluntary cash offers, securing 61.47% of its issued share capital and 99.74% of outstanding share options, granting majority control to the offeror. This change in ownership will reshape the company's capital structure and influence corporate decisions. The offers were not extended beyond the March 31, 2026 deadline, leaving only 20,000 share options outstanding. The latest analyst rating for WuXi XDC (HK:2268) is a Buy with a price target of HK$82.00.

Tip Ranks

Founder Fubon CSI Medicine and Medical Device Innovation ETF

WuXi XDC Cash Offers Close With Offeror Gaining Majority Control

In a report released on March 28, from Orient Securities maintained a Buy rating on WuXi XDC Cayman, Inc., with a price target of HK$68.47.End of Quarter Sale - 50% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Currently, the analyst consensus on WuXi XDC Cayman, Inc. is a Strong Buy with an average price target of HK$83.23.

WuXi XDC Cayman, Inc. (2268) Receives a Buy from Orient Securities

CMB International has lowered the target price for WUXI XDC to 82 yuan, maintaining a "Buy" rating. It is expected that revenue will grow by 46.7% year-on-year in 2025, with adjusted net profit increasing by 69.9%. As of the end of last year, the backlog of uncompleted orders grew by 50.3% to 1.49 billion USD, and new signed orders increased by 41% to 1.33 billion USD. Management expects revenue growth to exceed 40% in 2026

AASTOCKS

CITIC International lowered the target price for WuXi XDC to 82 yuan, rating it as "Buy."

Goldman Sachs released a report stating that WuXi XDC's performance in the second half of last year met expectations, with revenue increasing by 35.9% year-on-year and net profit rising by 26.4% to RMB 735 million. Management's guidance for this year is in line with expectations, forecasting revenue growth of approximately 35% to 40% by 2026. Goldman Sachs has raised its adjusted net profit forecasts for 2026 to 2028 and maintained a "Buy" rating, with a slight decrease in the target price to HKD 85.9

Goldman Sachs slightly lowered the target price for WUXI XDC to 85.9 yuan, with this year's guidance in line with expectations

WUXI XDC rose 10.33%; WuXi AppTec rose 10.13%, with a transaction volume of HKD 1.254 billion; WuXi Biologics rose 4.38%, with a transaction volume of HKD 1.161 billion; Crystal International Holdings rose 1.46%, with a transaction volume of HKD 427 million; Kanglong Chemical rose 4.08%, with a market value of HKD 33.6 billion

HK Stock Alerts

Hong Kong Stock Movement: WUXI XDC's performance shows strong growth of 10.33%, UBS maintains "Buy" rating to support stock price rise

09888

01024

09988

00700

09896

09618

03939

00322

00883

On March 24th, Hong Kong stocks strengthened during the session, with the Hang Seng Index rising by 2.19% and the Hang Seng TECH Index increasing by 1.67%. The internet content and retail sectors performed actively, with heavyweight leaders such as Tencent Holdings and Alibaba driving the market higher. Although there is still pressure at high levels, the bullish momentum continues, with Tencent and Alibaba leading the trading volume

- On March 24, Hong Kong's major stock indices rose amidst a positive sentiment, with the Hang Seng Index gaining 2.19% to 24,915.76 points.  
- The market witnessed upward movements in the internet content and retail sectors, while oil and gas exploration stocks generally declined due to weaker international oil prices.  
- Investors remain cautious despite gains, focusing on Hong Kong's export performance, retail sales data, and currency fluctuations.

Market Pulse

BIDU-SW

KUAISHOU-W

BABA-W

TENCENT

MNSO

JD-SW

WANGUO GOLD GP

TINGYI

CNOOC

Krne Csi China Internet

E Fund CSI HK Connect Internet ETF

Amplify Online Retail ETF

Tencent Holdings Limited

Alibaba

SPDR S&P Retail ETF

Global X E-commerce ETF

Tencent

CSOP HS TECH

Hang Seng TECH Index

VanEck Retail ETF

Hwabao CSI HK Equities Internet ETF

ProShares Online Retail

Emerging Markets Internet ETF

Hang Seng Index

KraneShares 2x Long BABA Daily ETF

BABA 2x Long Daily ETF - GraniteShares

Hong Kong stock market intraday | Hang Seng Index rises 2.19% to return to 24,900 points, with internet retail leading the gains

WUXI XDC(02268.HK)